Insider transactions

EDGAR

BIO-TECHNE Corp

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
2 transactions, 8,612 shares
Sum of shares × price per share: 437,177.56

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 152

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-01 Filed 2026-11-03Kelderman Kim Director · Officer: Chief Executive Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,38572.66
173,294.1

Derived: shares × price per share. Exact value 173294.10.

80,509Direct (D) No— Open filing 0000914190-26-000175 Read from the filing’s XML Dispute this row
2026-11-01 Filed 2026-11-03Hippel James Officer: CFO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)11,5450—181,816Direct (D) No— Open filing 0000914190-26-000174 Read from the filing’s XML Dispute this row
2026-11-01 Filed 2026-11-03Hippel James Officer: CFO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5,09672.66
370,275.36

Derived: shares × price per share. Exact value 370275.36.

176,720Direct (D) No— Open filing 0000914190-26-000174 Read from the filing’s XML Dispute this row
2026-11-01 Filed 2026-11-03Hippel James Officer: CFO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (11,545)
Disposed (D)11,5450—11,544Direct (D) No
F5, F9
  • F5 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
  • F9 11,545 restricted stock units vest on 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
Open filing 0000914190-26-000174 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-11-02BAUMGARTNER ROBERT V Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7500—59,634Direct (D) No— Open filing 0000914190-26-000155 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-11-02Bushman Julie L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7500—11,525Direct (D) No— Open filing 0000914190-26-000156 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-11-02Seth Alpna Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7500—18,161Direct (D) No— Open filing 0000914190-26-000161 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-11-02KEEGAN JOSEPH D Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7500—18,161Direct (D) No— Open filing 0000914190-26-000158 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-11-02HIGGINS JOHN L Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7500—80,004Direct (D) No— Open filing 0000914190-26-000157 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-11-02Klimovsky Judith V. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7500—6,532Direct (D) No— Open filing 0000914190-26-000160 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-11-02Vessey Rupert Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7500—13,737Direct (D) No— Open filing 0000914190-26-000162 Read from the filing’s XML Dispute this row
2026-10-29 Filed 2026-11-02Herr Amy E. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)2,7500—5,430Direct (D) No— Open filing 0000914190-26-000159 Read from the filing’s XML Dispute this row
2026-09-28 Filed 2026-09-30HIGGINS JOHN L Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)15,9400—82,816Direct (D) No— Open filing 0000914190-26-000142 Read from the filing’s XML Dispute this row
2026-09-28 Filed 2026-09-30HIGGINS JOHN L Director
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5,56272.51
403,300.62

Derived: shares × price per share. Exact value 403300.62.

77,254Direct (D) No— Open filing 0000914190-26-000142 Read from the filing’s XML Dispute this row
2026-09-28 Filed 2026-09-30HIGGINS JOHN L Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (15,940) — exercise price 25.30
Disposed (D)15,9400—0Direct (D) No— Open filing 0000914190-26-000142 Read from the filing’s XML Dispute this row
2026-09-22 Filed 2026-09-24BAUMGARTNER ROBERT V Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)15,9400—62,443Direct (D) No— Open filing 0000914190-26-000139 Read from the filing’s XML Dispute this row
2026-09-22 Filed 2026-09-24BAUMGARTNER ROBERT V Director
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)5,55972.55
403,305.45

Derived: shares × price per share. Exact value 403305.45.

56,884Direct (D) No— Open filing 0000914190-26-000139 Read from the filing’s XML Dispute this row
2026-09-22 Filed 2026-09-24BAUMGARTNER ROBERT V Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Options (Right to Buy) — underlying Common Stock (15,940) — exercise price 25.30
Disposed (D)15,9400—0Direct (D) No— Open filing 0000914190-26-000139 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Kelderman Kim Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (57,590)
Acquired (A)57,5900—57,590Direct (D) No
F7, F12
  • F7 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F12 19,197 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 19,196 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000133 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Kelderman Kim Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (93,582)
Acquired (A)93,5820—93,582Direct (D) No
F7, F13
  • F7 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F13 93,582 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000133 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Bohnen Shane Officer: SVP - General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (11,344)
Acquired (A)11,3440—11,344Direct (D) No
F6, F11
  • F6 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F11 3,781 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 3,782 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000134 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Bohnen Shane Officer: SVP - General Counsel
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (18,432)
Acquired (A)18,4320—18,432Direct (D) No
F6, F12
  • F6 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F12 18,432 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000134 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Crouse Steven C. Officer: President - Diag Spatial Bi
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (8,702)
Acquired (A)8,7020—8,702Direct (D) No
F8, F15
  • F8 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F15 2,901 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 2,900 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000129 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Crouse Steven C. Officer: President - Diag Spatial Bi
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,140)
Acquired (A)14,1400—14,140Direct (D) No
F8, F16
  • F8 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F16 14,140 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000129 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Herr Amy E. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (1,381)
Acquired (A)1,3810—1,381Indirect (I) By significant otherNo
F7, F11
  • F7 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F11 460 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 461 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000131 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Geist William Officer: PRESIDENT, PROTEIN SCIENCES
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (14,762)
Acquired (A)14,7620—14,762Direct (D) No
F5, F10
  • F5 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F10 4,921 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 4,920 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000130 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Geist William Officer: PRESIDENT, PROTEIN SCIENCES
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (23,985)
Acquired (A)23,9850—23,985Direct (D) No
F5, F11
  • F5 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F11 23,985 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000130 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Hippel James Officer: CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (22,438)
Acquired (A)22,4380—22,438Direct (D) No
F5, F11
  • F5 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
  • F11 7,479 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 7,480 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000132 Read from the filing’s XML Dispute this row
2026-08-17 Filed 2026-08-19Hippel James Officer: CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (36,459)
Acquired (A)36,4590—36,459Direct (D) No
F5, F12
  • F5 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
  • F12 36,459 restricted stock units vest on 8/17/2029.
Open filing 0000914190-26-000132 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)21,7360—93,849Direct (D) No— Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)10,95572.40
793,142

Derived: shares × price per share. Exact value 793142.00.

82,894Direct (D) No— Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance Stock Options (Right to Buy) — underlying Common Stock (22,044) — exercise price 84.61
Disposed (D)22,0440—1,837Direct (D) No
F1
  • F1 On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,837 performance options. The remainder of the performance options were forfeited.
Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance Stock Options (Right to Buy) — underlying Common Stock (23,949) — exercise price 68.54
Disposed (D)23,9490—1,996Direct (D) No
F2
  • F2 On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,996 performance options. The remainder of the performance options were forfeited.
Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Performance Restricted Stock Units — underlying Common Stock (683)
Disposed (D)6830—8,190Direct (D) No
F3, F4
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F4 On 8/15/2026, the Board of Directors authorized discretionary vesting for 683 performance RSUs. The remainder of the performance RSUs were forfeited.
Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance Restricted Stock Units — underlying Common Stock (8,190)
Disposed (D)8,1900—0Direct (D) No
F3, F4
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F4 On 8/15/2026, the Board of Directors authorized discretionary vesting for 683 performance RSUs. The remainder of the performance RSUs were forfeited.
Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Performance Restricted Stock Units — underlying Common Stock (725)
Disposed (D)7250—8,698Direct (D) No
F3, F5
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F5 On 8/15/2026, the Board of Directors authorized discretionary vesting for 725 performance RSUs. The remainder of the performance RSUs were forfeited.
Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance Restricted Stock Units — underlying Common Stock (8,698)
Disposed (D)8,6980—0Direct (D) No
F3, F5
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F5 On 8/15/2026, the Board of Directors authorized discretionary vesting for 725 performance RSUs. The remainder of the performance RSUs were forfeited.
Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (8,543)
Disposed (D)8,5430—8,544Direct (D) No
F3, F6
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F6 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Kelderman Kim Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (11,785)
Disposed (D)11,7850—23,569Direct (D) No
F3, F7
  • F3 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F7 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.
Open filing 0000914190-26-000169 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Bohnen Shane Officer: SVP - General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)4,4200—11,773Direct (D) No— Open filing 0000914190-26-000167 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Bohnen Shane Officer: SVP - General Counsel
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,36672.40
98,898.4

Derived: shares × price per share. Exact value 98898.40.

10,407Direct (D) No— Open filing 0000914190-26-000167 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Bohnen Shane Officer: SVP - General Counsel
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance Stock Option (Right to Buy) — underlying Common Stock (11,929) — exercise price 84.61
Disposed (D)11,9290—995Direct (D) No
F1
  • F1 On 8/15/2026, the Board of Directors authorized discretionary vesting for 995 performance options. The remainder of the performance options were forfeited.
Open filing 0000914190-26-000167 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Bohnen Shane Officer: SVP - General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Performance Restricted Stock Units — underlying Common Stock (370)
Disposed (D)3700—4,432Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F3 On 8/15/2026, the Board of Directors authorized discretionary vesting for 370 performance RSUs. The remainder of the performance RSUs were forfeited.
Open filing 0000914190-26-000167 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Bohnen Shane Officer: SVP - General Counsel
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance Restricted Stock Units — underlying Common Stock (4,432)
Disposed (D)4,4320—0Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F3 On 8/15/2026, the Board of Directors authorized discretionary vesting for 370 performance RSUs. The remainder of the performance RSUs were forfeited.
Open filing 0000914190-26-000167 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Bohnen Shane Officer: SVP - General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (49)
Disposed (D)490—0Direct (D) No
F2, F4
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F4 49 restricted stock units vest on 8/15/2026.
Open filing 0000914190-26-000167 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Bohnen Shane Officer: SVP - General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (1,669)
Disposed (D)1,6690—1,669Direct (D) No
F2, F5
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F5 1,669 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
Open filing 0000914190-26-000167 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Bohnen Shane Officer: SVP - General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (2,332)
Disposed (D)2,3320—4,664Direct (D) No
F2, F6
  • F2 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  • F6 2,332 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028.
Open filing 0000914190-26-000167 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Hippel James Officer: CFO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)9,9800—174,694Direct (D) No— Open filing 0000914190-26-000171 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Hippel James Officer: CFO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)4,42372.40
320,225.2

Derived: shares × price per share. Exact value 320225.20.

170,271Direct (D) No— Open filing 0000914190-26-000171 Read from the filing’s XML Dispute this row
2026-08-15 Filed 2026-11-02Hippel James Officer: CFO
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Derivative security: Performance Stock Options (Right to Buy) — underlying Common Stock (34,443) — exercise price 84.61
Disposed (D)34,4430—2,871Direct (D) No
F1
  • F1 On 8/15/2026, the Board of Directors authorized discretionary vesting for 2,871 performance options. The remainder of the performance options were forfeited.
Open filing 0000914190-26-000171 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–50 of 607

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
BlackRock, Inc. Partly reported under another manager14,250,400 SH1,032,726,512 dollarsHigher by 224,584 Prior quarter: 14,025,816Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 10,250,628 SH742,863,011 dollarsHigher by 32,070 Prior quarter: 10,218,558Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
HBK INVESTMENTS L P 7,732,128 SH560,347,316 dollarsHigher by 907,128 Prior quarter: 6,825,000Open filing 0001011443-26-000022 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 6,348,862 SH460,102,029 dollarsLower by 157,498 Prior quarter: 6,506,360Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
FIL Ltd Partly reported under another manager6,272,729 SH454,584,671 dollarsHigher by 6,268,781 Prior quarter: 3,948Open filing 0000318989-26-000202 Filed 2026-11-10 Dispute this row
STATE STREET CORP Partly reported under another manager6,045,884 SH438,145,213 dollarsHigher by 65,514 Prior quarter: 5,980,370Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager5,431,896 SH393,097,407 dollarsHigher by 80,432 Prior quarter: 5,351,464Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager4,144,123 SH300,324,598 dollarsLower by 3,199,201 Prior quarter: 7,343,324Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
MILLENNIUM MANAGEMENT LLC 4,091,871 SH296,537,891 dollarsHigher by 3,102,838 Prior quarter: 989,033Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row
Invesco Ltd. Partly reported under another manager3,775,138 SH273,584,252 dollarsLower by 1,211,286 Prior quarter: 4,986,424Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
Balyasny Asset Management L.P. 3,403,731 SH246,668,386 dollarsHigher by 2,566,861 Prior quarter: 836,870Open filing 0001193125-26-463223 Filed 2026-11-16 Dispute this row
Ruane, Cunniff Goldfarb L.P. 3,342,837 SH242,255,397 dollarsLower by 6,004 Prior quarter: 3,348,841Open filing 0000919574-26-007856 Filed 2026-11-16 Dispute this row
MORGAN STANLEY Partly reported under another manager3,329,471 SH241,286,910 dollarsLower by 3,045,246 Prior quarter: 6,374,717Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Walleye Capital LLC Option: Call 3,296,500 SH238,897,355 dollarsHigher by 3,285,900 Prior quarter: 10,600Open filing 0001758720-26-000007 Filed 2026-11-13 Dispute this row
WHITEBOX ADVISORS LLC 2,623,801 SH190,146,858 dollarsHigher by 523,800 Prior quarter: 2,100,001Open filing 0001257391-26-000008 Filed 2026-11-16 Dispute this row
D. E. Shaw Co., Inc. Partly reported under another manager2,531,648 SH183,468,531 dollarsHigher by 2,303,169 Prior quarter: 228,479Open filing 0001104659-26-128287 Filed 2026-11-16 Dispute this row
UBS Group AG Partly reported under another manager2,492,348 SH180,620,459 dollarsHigher by 13,741 Prior quarter: 2,478,607Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Qube Research Technologies Ltd 2,379,411 SH172,435,915 dollarsNot in the prior quarter’s filings read Open filing 0001729829-26-000018 Filed 2026-11-13 Dispute this row
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ Partly reported under another manager2,321,733 SH168,229,821 dollarsLower by 424,729 Prior quarter: 2,746,462Open filing 0000912938-26-001073 Filed 2026-11-12 Dispute this row
NEUBERGER BERMAN GROUP LLC 2,257,292 SH163,585,964 dollarsLower by 587,400 Prior quarter: 2,844,692Open filing 0001465109-26-000128 Filed 2026-11-13 Dispute this row
BARCLAYS PLC Partly reported under another manager2,250,445 SH163,089,749 dollarsHigher by 2,033,426 Prior quarter: 217,019Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
CITIGROUP INC Partly reported under another manager1,760,388 SH127,575,318 dollarsHigher by 1,315,243 Prior quarter: 445,145Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager1,691,899 SH123,103,102 dollarsLower by 170,906 Prior quarter: 1,862,805Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,679,804 SH121,735,396 dollarsHigher by 57,388 Prior quarter: 1,622,416Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
MAVERICK CAPITAL LTD 1,535,610 SH111,285,657 dollarsUnchanged Prior quarter: 1,535,610Open filing 0000947871-26-001025 Filed 2026-11-16 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager1,374,688 SH99,623,639 dollarsHigher by 1,128,616 Prior quarter: 246,072Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
AQR Arbitrage LLC 1,294,273 SH93,627,709 dollarsHigher by 532,405 Prior quarter: 761,868Open filing 0001167456-26-000005 Filed 2026-11-16 Dispute this row
FIRST TRUST ADVISORS LP 1,285,722 SH93,176,255 dollarsLower by 88,130 Prior quarter: 1,373,852Open filing 0001445546-26-008622 Filed 2026-11-12 Dispute this row
MAIRS POWER INC 1,273,645 SH92,301,038 dollarsLower by 1,427,053 Prior quarter: 2,700,698Open filing 0001172661-26-005199 Filed 2026-11-16 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager1,259,751 SH91,294,155 dollarsLower by 51,437 Prior quarter: 1,311,188Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager1,228,939 SH89,061,210 dollarsHigher by 527,199 Prior quarter: 701,740Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
SUSQUEHANNA INTERNATIONAL GROUP, LLP Option: Call Partly reported under another manager1,161,500 SH84,173,905 dollarsHigher by 1,099,900 Prior quarter: 61,600Open filing 0001446194-26-000009 Filed 2026-11-16 Dispute this row
GLAZER CAPITAL, LLC 1,152,274 SH83,505 dollarsHigher by 952,274 Prior quarter: 200,000Open filing 0001076809-26-000174 Filed 2026-11-17 Dispute this row
BROWN ADVISORY INC Partly reported under another manager1,090,930 SH79,059,640 dollarsLower by 196,628 Prior quarter: 1,287,558Open filing 0001345929-26-000049 Filed 2026-11-16 Dispute this row
FMR LLC Partly reported under another manager1,088,114 SH78,855,641 dollarsLower by 11,706,670 Prior quarter: 12,794,784Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
Madison Asset Management, LLC 1,017,391 SH73,730,350 dollarsLower by 46,082 Prior quarter: 1,063,473Open filing 0001954889-26-000026 Filed 2026-11-12 Dispute this row
ALLIANCEBERNSTEIN L.P. Partly reported under another manager1,011,821 SH73,326,662 dollarsLower by 990,205 Prior quarter: 2,002,026Open filing 0001109448-26-000342 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager941,734 SH68,247,491 dollarsLower by 13,503 Prior quarter: 955,237Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Decagon Asset Management LLP Option: Call 937,300 SH67,926,131 dollarsHigher by 808,700 Prior quarter: 128,600Open filing 0001950677-26-000026 Filed 2026-11-16 Dispute this row
Capital Research Global Investors Partly reported under another manager937,246 SH67,922,218 dollarsLower by 1,684,644 Prior quarter: 2,621,890Open filing 0001422848-26-000129 Filed 2026-11-12 Dispute this row
NATIXIS ADVISORS, LLC Partly reported under another manager920,088 SH66,679 dollarsHigher by 101,183 Prior quarter: 818,905Open filing 0001018331-26-000013 Filed 2026-11-13 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager919,092 SH66,735,220 dollarsHigher by 122,091 Prior quarter: 797,001Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager915,328 SH66,333,826 dollarsLower by 362,868 Prior quarter: 1,278,196Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
TIG Advisors, LLC 891,900 SH64,635,993 dollarsHigher by 49,708 Prior quarter: 842,192Open filing 0000919574-26-008097 Filed 2026-11-16 Dispute this row
VANGUARD FIDUCIARY TRUST CO 884,192 SH64,077,394 dollarsHigher by 4,955 Prior quarter: 879,237Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
GENEVA CAPITAL MANAGEMENT LLC Partly reported under another manager884,168 SH64,075,632 dollarsLower by 127,909 Prior quarter: 1,012,077Open filing 0001009232-26-000014 Filed 2026-11-09 Dispute this row
TUDOR INVESTMENT CORP ET AL 855,749 SH62,016,130 dollarsLower by 87,538 Prior quarter: 943,287Open filing 0000902664-26-004567 Filed 2026-11-16 Dispute this row
Man Group plc Partly reported under another manager769,967 SH55,799,509 dollarsHigher by 409,967 Prior quarter: 360,000Open filing 0001637460-26-000004 Filed 2026-11-16 Dispute this row
Magnetar Financial LLC Partly reported under another manager761,911 SH55,215,690 dollarsUnchanged Prior quarter: 761,911Open filing 0001104659-26-126450 Filed 2026-11-13 Dispute this row
TORONTO DOMINION BANK Partly reported under another manager718,520 SH52,071,174 dollarsHigher by 693,923 Prior quarter: 24,597Open filing 0002052595-26-000123 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • SNYDER CAPITAL MANAGEMENT L P 3,163,816 SH
  • Sixth Street Partners Management Company, L.P. 1,622,416 SH
  • NORGES BANK 1,413,639 SH
  • SCHRODER INVESTMENT MANAGEMENT GROUP 1,410,943 SH
  • Stephens Investment Management Group LLC 944,697 SH
  • Decagon Asset Management LLP 564,664 SH
  • Capital World Investors 536,962 SH
  • SOROS FUND MANAGEMENT LLC 535,400 SH
  • FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ 470,675 SH
  • Clearbridge Investments, LLC 428,316 SH
  • Sand Grove Capital Management LLP 370,990 SH
  • Torque Asset Management LLC 328,429 SH
  • LORD, ABBETT CO. LLC 289,060 SH
  • Kryger Capital LLC 274,290 SH
  • Sagefield Capital LP 209,647 SH
  • Hudson Bay Capital Management LP 200,000 SH
  • WCM INVESTMENT MANAGEMENT, LLC 197,933 SH
  • Impax Asset Management Group plc 195,000 SH
  • NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 133,233 SH
  • Montanaro Asset Management Ltd 126,335 SH
  • Ceredex Value Advisors LLC 120,139 SH
  • Ananym Capital Management, LP 120,000 SH
  • FRED ALGER MANAGEMENT, LLC 101,607 SH
  • CAPITAL COUNSEL LLC/NY 73,850 SH
  • Jupiter Topco LLC 68,202 SH
  • Fortress Investment Group LLC 67,000 SH
  • BLI - Banque de Luxembourg Investments 57,500 SH
  • Oak Thistle LLC 57,274 SH
  • Sciencast Management LP 56,471 SH
  • Hilton Capital Management, LLC 53,568 SH
  • HAHN CAPITAL MANAGEMENT LLC 50,766 SH
  • TOKIO MARINE ASSET MANAGEMENT CO LTD 49,600 SH
  • Pacer Advisors, Inc. 48,201 SH
  • Vestmark Advisory Solutions, Inc. 44,928 SH
  • Caption Management, LLC 42,000 SH
  • Henshaw Capital LLC 39,448 SH
  • Chicago Capital Management, LLC 37,509 SH
  • SG Americas Securities, LLC 35,618 SH
  • ROWLANDMILLER PARTNERS.ADV 33,341 SH
  • B. Metzler seel. Sohn Co. AG 31,091 SH
  • Jupiter Research Capital (Asia) Ltd 30,318 SH
  • Bridgewater Associates, LP 26,750 SH
  • 2Xideas AG 24,613 SH
  • Summit Trail Advisors, LLC 22,807 SH
  • Sanchez Wealth Management Group 20,536 SH
  • Generali Investments Towarzystwo Funduszy Inwestycyjnych 20,500 SH
  • Legal Advantage Investments, Inc. 17,335 SH
  • Verdence Capital Advisors LLC 14,342 SH
  • Olympiad Research LP 14,154 SH
  • AZZAD ASSET MANAGEMENT INC /ADV 14,008 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

Showing 1–16 of 16

House members’ trades in this company, newest report first, as filed
MemberTransaction dateTypeAmountOwnerReport
Hon. April McClain Delaney (MD06)2026-04-08Sale$1,001 - $15,000DC2026-05-06
Hon. April McClain Delaney (MD06)2026-03-26Sale (partial)$1,001 - $15,000DC2026-04-06
Hon. April McClain Delaney (MD06)2026-02-24Sale (partial)$1,001 - $15,000DC2026-03-10
Hon. April McClain Delaney (MD06)2026-01-28Sale (partial)$1,001 - $15,000DC2026-02-02
Hon. April McClain Delaney (MD06)2025-12-02Purchase$1,001 - $15,000DC2026-01-05
Hon. April McClain Delaney (MD06)2025-12-05Purchase$1,001 - $15,000DC2026-01-05
Hon. April McClain Delaney (MD06)2025-10-22Purchase$1,001 - $15,000DC2025-11-04
Hon. April McClain Delaney (MD06)2025-08-01Sale (partial)$1,001 - $15,000DC2025-09-02
Hon. April McClain Delaney (MD06)2025-05-26Sale (partial)$1,001 - $15,000DC2025-07-02
Hon. Julie Johnson (TX32)2025-04-01Sale$1,001 - $15,000JT2025-05-14
Hon. Rob Bresnahan (PA08)2025-04-08Sale$1,001 - $15,0002025-05-08
Hon. April McClain Delaney (MD06)2025-04-09Purchase$1,001 - $15,000DC2025-05-02
Hon. April McClain Delaney (MD06)2025-04-29Purchase$1,001 - $15,000DC2025-05-02
Hon. Rob Bresnahan (PA08)2025-02-25Purchase$1,001 - $15,0002025-03-27
Hon. Greg Gianforte (MT00)2020-10-13Sale (partial)$1,001 - $15,000JT2020-11-09
Hon. Greg Gianforte (MT00)2019-01-24Sale (partial)$1,001 - $15,000JT2019-03-06

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
FMR LLC COMMON STOCK0.71,088,114.2709/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-26-002681 Dispute this row
Abigail P. Johnson COMMON STOCK0.71,088,114.2709/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 2Open filing 0000315066-26-002681 Dispute this row
FMR LLC COMMON STOCK8.112,754,783.6406/30/2026 Filed 2026-08-06SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-001974 Dispute this row
Abigail P. Johnson COMMON STOCK8.112,754,783.6406/30/2026 Filed 2026-08-06SCHEDULE 13G/AAmendment 1Open filing 0000315066-26-001974 Dispute this row
FMR LLC COMMON STOCK5.07,859,928.3303/31/2026 Filed 2026-05-06SCHEDULE 13GOpen filing 0000315066-26-001101 Dispute this row
Abigail P. Johnson COMMON STOCK5.07,859,928.3303/31/2026 Filed 2026-05-06SCHEDULE 13GOpen filing 0000315066-26-001101 Dispute this row
Vanguard Capital Management Common Stock7.3811,559,57103/31/2026 Filed 2026-04-29SCHEDULE 13GOpen filing 0002100119-26-000207 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-26SCHEDULE 13G/AAmendment 13Open filing 0000102909-26-000769 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK2.23,350,81809/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 3Open filing 0000080255-25-000801 Dispute this row
T. Rowe Price Associates, Inc. COMMON STOCK5.68,848,15006/30/2025 Filed 2025-08-14SCHEDULE 13G/AAmendment 2Open filing 0000080255-25-000570 Dispute this row
BlackRock, Inc. Common Stock7.011,011,55606/30/2025 Filed 2025-07-16SCHEDULE 13G/AAmendment 4Open filing 0002052113-25-002485 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,722,084 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015138,466
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,828

Filings made before the SEC required XML are listed, not extracted.

Back to BIO-TECHNE Corp